Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have been assigned an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $5.56.

Several equities analysts have recently weighed in on ADMP shares. Zacks Investment Research lowered shares of Green Plains Partners from a “buy” rating to a “hold” rating in a research report on Friday. Dawson James began coverage on shares of Adamis Pharmaceuticals in a report on Tuesday, July 2nd. They issued a “buy” rating for the company. Raymond James reiterated a “buy” rating on shares of Canadian Natural Resources in a report on Friday, May 10th. Finally, B. Riley reiterated a “buy” rating on shares of Brightcove in a report on Tuesday.

Shares of NASDAQ:ADMP traded down $0.03 during trading hours on Friday, hitting $1.18. 215,217 shares of the company’s stock traded hands, compared to its average volume of 587,921. Adamis Pharmaceuticals has a 52 week low of $1.09 and a 52 week high of $4.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.24 and a current ratio of 1.53. The company’s fifty day simple moving average is $1.31. The stock has a market cap of $55.80 million, a P/E ratio of -1.18 and a beta of 1.36.

Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.04). Adamis Pharmaceuticals had a negative net margin of 239.53% and a negative return on equity of 94.94%. The business had revenue of $4.91 million for the quarter, compared to the consensus estimate of $5.95 million. Analysts expect that Adamis Pharmaceuticals will post -0.43 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale acquired a new position in shares of Adamis Pharmaceuticals in the first quarter worth about $3,360,000. National Asset Management Inc. boosted its holdings in shares of Adamis Pharmaceuticals by 28.9% in the first quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock worth $64,000 after buying an additional 6,710 shares during the period. Leisure Capital Management boosted its holdings in shares of Adamis Pharmaceuticals by 4.5% in the first quarter. Leisure Capital Management now owns 115,724 shares of the specialty pharmaceutical company’s stock worth $244,000 after buying an additional 4,967 shares during the period. Wedbush Securities Inc. acquired a new position in shares of Adamis Pharmaceuticals in the first quarter worth about $39,000. Finally, Virtu Financial LLC acquired a new position in shares of Adamis Pharmaceuticals in the first quarter worth about $43,000. Institutional investors own 21.79% of the company’s stock.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Further Reading: Convertible Shares

Analyst Recommendations for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.